eClerx Services has also formed strong bullish candlestick pattern on the daily charts with above average volumes as the stock jumped more than 6 percent to Rs 1,715, the highest closing level since January 20, 2022. The stock has seen a breakout of last four-day consolidation.
ICICI Securities has a "buy" rating on Gujarat Fluorochemicals, Archean Chemical, Tatva Chintan, EPL, Chemplast Sanmar, PCBL in the specialty chemicals basket, along with a "hold" call for industry leader SRF.
KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 974 in its research report dated February 10, 2023.
YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1095 in its research report dated February 07, 2023.
Healthcare Global Enterprises has broken out from the horizontal channel on the weekly charts. Price breakout is accompanied by jump in volumes. It is placed above all important moving averages, which indicates bullish trend on all time frames.
Given the subdued environment, the index may touch its August lows of around 17,150 and if that gets broken, then falling below psychological 17,000 mark can't be ruled out in coming sessions, with hurdle on the upside at 17,700-17,800 levels
KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1252 in its research report dated August 10, 2022.
"What a great setup we are having at Greenply Industries -- precise bullish BAT pattern which got completed at 0.886 ratio on the daily chart with N-wave formation near the potential reversal zone of Rs 170-175."
YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1355 in its research report date May 25, 2022.
KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1252 in its research report dated May 24, 2022.
KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1456 in its research report dated March 28, 2022.
The board has set us a target to more than double our revenue and profit from the FY'20 levels by FY'23, both through organic as well as inorganic routes.